180 related articles for article (PubMed ID: 21343581)
1. Targeting immune dysregulation in myelodysplastic syndromes.
Olnes MJ; Sloand EM
JAMA; 2011 Feb; 305(8):814-9. PubMed ID: 21343581
[TBL] [Abstract][Full Text] [Related]
2. Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions.
Sloand EM; Olnes MJ; Shenoy A; Weinstein B; Boss C; Loeliger K; Wu CO; More K; Barrett AJ; Scheinberg P; Young NS
J Clin Oncol; 2010 Dec; 28(35):5166-73. PubMed ID: 21041705
[TBL] [Abstract][Full Text] [Related]
3. Immunomodulatory treatment of myelodysplastic syndromes: antithymocyte globulin, cyclosporine, and alemtuzumab.
Parikh AR; Olnes MJ; Barrett AJ
Semin Hematol; 2012 Oct; 49(4):304-11. PubMed ID: 23079060
[TBL] [Abstract][Full Text] [Related]
4. Novel immunosuppressive strategies for bone marrow failure syndromes: a focus on alemtuzumab.
Selleri C; Serio B; Risitano AM
Mini Rev Med Chem; 2011 Jun; 11(6):536-43. PubMed ID: 21561402
[TBL] [Abstract][Full Text] [Related]
5. [Myelodysplastic syndromes. Diagnosis and therapeutic strategies].
Aul C; Giagounidis A; Germing U; Ganser A
Med Klin (Munich); 2002 Nov; 97(11):666-76. PubMed ID: 12434275
[TBL] [Abstract][Full Text] [Related]
6. The use of selective immunosuppressive therapy on myelodysplastic syndromes in targeted populations results in good response rates and avoids treatment-related disease progression.
Xiao L; Qi Z; Qiusheng C; Li X; Luxi S; Lingyun W
Am J Hematol; 2012 Jan; 87(1):26-31. PubMed ID: 22038646
[TBL] [Abstract][Full Text] [Related]
7. Immunologic aspects of hypoplastic myelodysplastic syndrome.
Calado RT
Semin Oncol; 2011 Oct; 38(5):667-72. PubMed ID: 21943673
[TBL] [Abstract][Full Text] [Related]
8. Immunosuppressive therapy for myelodysplastic syndromes.
Dobbelstein C; Ganser A
Curr Pharm Des; 2012; 18(22):3184-9. PubMed ID: 22571697
[TBL] [Abstract][Full Text] [Related]
9. Mycobacterium haemophilum infection after alemtuzumab treatment.
Kamboj M; Louie E; Kiehn T; Papanicolaou G; Glickman M; Sepkowitz K
Emerg Infect Dis; 2008 Nov; 14(11):1821-3. PubMed ID: 18976587
[No Abstract] [Full Text] [Related]
10. The role of the immune system in myelodysplasia: implications for therapy.
Sloand EM; Rezvani K
Semin Hematol; 2008 Jan; 45(1):39-48. PubMed ID: 18179968
[TBL] [Abstract][Full Text] [Related]
11. Identification of campath-1 (CD52) as novel drug target in neoplastic stem cells in 5q-patients with MDS and AML.
Blatt K; Herrmann H; Hoermann G; Willmann M; Cerny-Reiterer S; Sadovnik I; Herndlhofer S; Streubel B; Rabitsch W; Sperr WR; Mayerhofer M; Rülicke T; Valent P
Clin Cancer Res; 2014 Jul; 20(13):3589-602. PubMed ID: 24799522
[TBL] [Abstract][Full Text] [Related]
12. Effect of cA2 anti-tumor necrosis factor-alpha antibody therapy on hematopoiesis of patients with myelodysplastic syndromes.
Boula A; Voulgarelis M; Giannouli S; Katrinakis G; Psyllaki M; Pontikoglou C; Markidou F; Eliopoulos GD; Papadaki HA
Clin Cancer Res; 2006 May; 12(10):3099-108. PubMed ID: 16707608
[TBL] [Abstract][Full Text] [Related]
13. T-cell large granular lymphocyte proliferation in myelodysplastic syndromes: Clinicopathological features and prognostic significance.
Zhang X; Sokol L; Bennett JM; Moscinski LC; List A; Zhang L
Leuk Res; 2016 Apr; 43():18-23. PubMed ID: 26927701
[TBL] [Abstract][Full Text] [Related]
14. Real life experience with alemtuzumab treatment of patients with lower-risk MDS and a hypocellular bone marrow.
Neukirchen J; Platzbecker U; Sockel K; Tsamaloukas A; Haas R; Germing U
Ann Hematol; 2014 Jan; 93(1):65-9. PubMed ID: 23934199
[TBL] [Abstract][Full Text] [Related]
15. Long-term improvement of hematopoiesis following cyclosporine treatment in a patient with myelodysplastic syndrome.
Berer A; Ohler L; Simonitsch I; Thalhammer R; Lechner K; Geissler K
Wien Klin Wochenschr; 1999 Oct; 111(19):815-8. PubMed ID: 10568013
[TBL] [Abstract][Full Text] [Related]
16. Delayed attainment of full donor chimaerism following alemtuzumab-based reduced-intensity conditioning haematopoeitic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes is associated with improved outcomes.
Lim ZY; Pearce L; Ho AY; Barber L; Ingram W; Usai M; Tobal K; Devereux S; Pagliuca A; Mufti GJ
Br J Haematol; 2007 Aug; 138(4):517-26. PubMed ID: 17608767
[TBL] [Abstract][Full Text] [Related]
17. Reconstitution of the T-cell repertoire following treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with B-cell chronic lymphocytic leukaemia.
Rezvany MR; Tehrani MJ; Karlsson C; Lundin J; Rabbani H; Osterborg A; Mellstedt H
Br J Haematol; 2006 Nov; 135(4):475-85. PubMed ID: 16995884
[TBL] [Abstract][Full Text] [Related]
18. Update on the science of myelodysplastic syndromes.
Ridgeway JA; Fechter L; Murray C; Borràs N
Clin J Oncol Nurs; 2012 Jun; 16 Suppl():9-22. PubMed ID: 22641281
[TBL] [Abstract][Full Text] [Related]
19. Outcomes following 50 mg versus 100 mg alemtuzumab in reduced-intensity conditioning stem cell transplants for acute myeloid leukaemia and poor risk myelodysplasia.
Tholouli E; Liakopoulou E; Greenfield HM; Shaw BE; Tauro S; Byrne JL; Dennis M; Burthem J; Lucas GS; Craddock C; Russell NH; Liu Yin JA
Br J Haematol; 2008 Jun; 142(2):318-20. PubMed ID: 18492100
[No Abstract] [Full Text] [Related]
20. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
Lü TM; Yang SL; Wu WZ; Tan JM
Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]